Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Upstart Holdings Inc (UPST) Price & Performance

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.

Upstart Holdings trades at $23.83, showing modest daily gains of 0.34% but remains in a bearish technical trend. The company reported mixed Q2 2026 earnings with $0.16 EPS missing expectations of $0.18, though revenue growth accelerated to $1.02 billion in 2025 with positive net income of $54 million. Recent news highlights partnership expansions into HELOC and auto lending while the stock faces pressure near 52-week lows.

Despite recent profitability improvements, Upstart faces execution risks with three consecutive earnings misses and negative operating cash flow. Analyst consensus remains divided with a $38.13 price target suggesting 60% upside potential, but high valuation multiples and competitive pressures in consumer lending warrant caution for investors.